Core Viewpoint - The company, AoJing Medical, has received approval from the National Medical Products Administration for its absorbable composite bone repair material medical device, marking a significant advancement in the field of biomaterials [1] Group 1: Product Development - The company submitted the registration application for the absorbable composite bone repair material medical device in August 2024 [1] - The new product builds on existing technology (artificial bone repair material, registration number: 20193131531) by incorporating absorbable polyester materials [1] - The new material enhances strength and controllable degradation while maintaining excellent biocompatibility and bone healing promotion capabilities [1] Group 2: Intellectual Property and Innovation - AoJing Medical holds complete independent intellectual property rights for the absorbable composite bone repair material medical device [1] - The key technology of this product represents a major breakthrough in the field of bone repair materials and is considered original innovation in biomaterials [1] - This development opens a new pathway for the independent preparation of biomaterials, achieving an internationally leading level [1]

Core Viewpoint - The company, AoJing Medical (688613.SH), has received approval from the National Medical Products Administration for its absorbable composite bone repair material, enhancing its product portfolio in the bone repair materials sector [1] Product Development - The approved product incorporates absorbable polyester materials, improving strength and controllable degradation, which better addresses various clinical conditions for bone defect repair [1] - The product is developed independently by the company and possesses complete intellectual property rights, achieving an internationally leading technological level [1] Market Impact - The registration certificate for the new product enhances the company's product layout in the bone repair materials field, facilitating overall market expansion domestically [1] - Actual sales performance will depend on the product's competitiveness and market sales capabilities, with no current predictions available regarding its impact on the company's future operating performance [1]

Group 1 - The core point of the news is that BioVeda China RMB Investment Limited has reduced its shareholding in Aojing Medical Technology Co., Ltd., bringing its stake below 5% [18][19][23] - The shareholding before the reduction was 7,239,358 shares, accounting for 5.28% of the total shares [8] - After the reduction, BioVeda holds 6,850,430 shares, which is 5% of the total shares [9][10] Group 2 - The reduction was executed through block trading and centralized bidding on the Shanghai Stock Exchange [7][10] - The total number of shares reduced was 388,928, representing 0.28% of the total shares [20] - BioVeda has stated that it may continue to reduce its holdings in the next 12 months, adhering to relevant legal disclosure obligations [6][23] Group 3 - The reduction does not trigger a mandatory tender offer and will not change the controlling shareholder or actual controller of Aojing Medical [18][23] - BioVeda has confirmed that there are no restrictions on the rights of the shares held, such as pledges or freezes [11] - The company has complied with all relevant laws and regulations regarding the share reduction [20][33]

Core Viewpoint - The announcement details a share reduction plan by major shareholder Beijing Qilun Tianyou Venture Capital Co., Ltd. for Aojing Medical Technology Co., Ltd., indicating a planned reduction of up to 1,355,515 shares, which represents 1% of the total shares outstanding [3][6]. Group 1: Major Shareholder Information - As of the announcement date, Qilun Tianyou holds 8,468,000 shares, accounting for 6.18% of Aojing Medical's total shares [2]. - The shares held by Qilun Tianyou were acquired prior to the company's initial public offering and have been tradable since May 23, 2022 [2]. Group 2: Share Reduction Plan Details - Qilun Tianyou plans to reduce its holdings through centralized bidding and block trading, with a maximum reduction of 1,355,515 shares [3]. - The reduction will occur within three months following a 15-day period after the announcement, specifically from October 23, 2025, to January 23, 2026 [3]. Group 3: Compliance and Commitments - Qilun Tianyou has previously committed to not transferring or entrusting the management of its shares for twelve months following the company's stock listing [5]. - The current reduction plan is consistent with prior commitments made by the major shareholder [6]. Group 4: Other Shareholder Activities - BioVeda China RMB Investment Limited has also reduced its holdings, decreasing its stake to 5% after selling 388,928 shares, which is 0.28% of the total shares [12][13]. - The reduction by BioVeda does not trigger a change in control of the company and complies with relevant regulations [12][16].

Core Viewpoint - Qilin Tianyou plans to reduce its stake in AoJing Medical by up to 1% of the total shares, which amounts to a maximum of 1.3555 million shares, due to its own financial arrangements [1] Company Summary - AoJing Medical (688613.SH) has received a notice from Qilin Tianyou regarding its share reduction plan [1] - The reduction will be executed through centralized bidding and block trading methods [1] Stakeholder Actions - Qilin Tianyou intends to sell shares based on market conditions [1]

Group 1 - The core point of the article is that Aojing Medical (688613.SH) has received a notice from Qilun Tianyou regarding a share reduction plan [1] - Qilun Tianyou plans to reduce its holdings in Aojing Medical by up to 1.3555 million shares, which represents 1% of the total shares of Aojing Medical [1]

奥精医疗科技股份有限公司 证券代码：688613 证券简称：奥精医疗 公告编号：2025-052 关于持股 5%以上股东权益变动至 5%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 9 月 23 日收到公司股东 BioVeda 发来的《奥精医疗科技股 份有限公司简式权益变动报告书》，现将其有关权益变动情况公告如下： 一、本次权益变动情况 | （一）信息披露义务人基本情况 | | --- | | 企业名称 | BioVeda | China | RMB | Investment | | Limited | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 注册地址 | 3806 | Central | Plaza, | 18 | Harbour | Road, | Wanchai | HK | | 执行事务合伙人 | 不适用 | | | | | | | | | 成立时间 | 2008年9月30日 | ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-053 奥精医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东的基本情况 大股东最近一次减持情况 股东名称 减持数量 （股） 减持比例 减持期间 减持价格区间 （元/股） 前期减持计划 披露日期 奇伦天佑 600,000 0.449% 2023/4/21～ 2023/7/11 28.00-29.30 2023.3.21 二、减持计划的主要内容 股东名称 奇伦天佑 计划减持数量 不超过：1355515 股 计划减持比例 不超过：1% 减持方式及对应减持数 量 集中竞价减持，不超过：1355515 股 大宗交易减持，不超过：1355515 股 减持期间 2025 年 10 月 23 日～2026 年 1 月 23 日 拟减持股份来源 IPO 前取得 拟减持原因 自身资金安排 截至本公告披露日，奥精医疗科技股份有限公司（以下简称 "公司" 或"奥精医疗"）股东北京奇伦天佑创业投资有限公司（以 ...

奥精医疗科技股份有限公司 简式权益变动报告书 信息披露义务人：BioVeda China RMB Investment Limited 股份变动性质：减持股份 签署日期：2025年9月23日 1 上市公司：奥精医疗科技股份有限公司 上市地点：上海证券交易所 股票简称：奥精医疗 股票代码：688613 信息披露义务人声明 一、本权益变动报告书是依据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披 露内容与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信 息披露内容与格式准则第 16 号——上市公司收购报告书》及相关法律、法 规、规范性文件之规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的 规定，本报告书已全面披露信息披露义务人在奥精医疗科技股份有限公司 拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的持 股信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在奥 精医疗科技股份有限公司中拥有权益的股份。 四、信息披露义务人承诺本报告书不存在虚假记载 ...

Group 1 - The core point of the article is that Beijing Qilun Tianyou Venture Capital Co., Ltd., a shareholder holding 6.18% of Aojing Medical (688613), plans to reduce its stake by up to 1% through centralized bidding and block trading, amounting to no more than 1.3555 million shares [1]